Share this article
Share this article
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021.
A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 am E.T. and can be accessed by visiting the Events and Webcasts section of the Company s website: http://investors.proventionbio.com/events. The webcast will be archived on the Company s website for 30 days following the presentation.
Share this article
Share this article
RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of PROVENT (
PROtocol for coxsackievirus
E in healthy volu
NTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B (CVB) vaccine candidate, PRV-101. Provention is developing PRV-101 for the prevention of acute CVB infection and the potential delay or prevention of type 1 diabetes (T1D) and celiac disease.
CVB is a common enterovirus that frequently causes acute morbidity such as respiratory disease, meningitis, pericarditis, otitis, and hand-foot-mouth disease. CVB is also the leading cause of viral myocarditis, a common condition that can cause fatal arrythmia and lead to a serious chronic myocarditis that often needs heart transplantation. CVB infection is significantly associated with the development of T1D an